

IGLO Health Working Group: EDCTP – Advancing health resilience and innovation through global partnerships

Date:	01.07.2026
Place of the event:	Permanent Representation of Lithuania to the EU, Rue Belliard 41/43, Brussels
Written by:	Monika Čechmanová, junior consultant for research

Global Health EDCTP3

- Global Health EDCTP3 is the largest research funding partnership between the European Union and Africa and was established in 2021.
- Participation requires at least one sub-Saharan African entity and one EU entity, with scientific leadership often held by African partners.
- The partnership is built around three integrated pillars: clinical research, capacity strengthening, and collaboration and networks.
- Its scope focuses on major infectious diseases affecting sub-Saharan Africa.
- The partnership also addresses cross-cutting issues such as antimicrobial resistance, digital health solutions and the impact of the climate crisis.
- Its governance is shared between the EDCTP Association and the European Commission.
- Global Health EDCTP3 has 49 members from Europe and Africa.
- The total resources amount to EUR 1.84 billion, including EUR 890 million from the EU, EUR 550 million from the EDCTP Association and EUR 400 million from more than 50 contributing partners.
- Funding is provided through open calls.
- Global collaboration actions include call topics where co-funding contributions are scored under two of the three evaluation award criteria.
- The 2024 emergency call on the mpox outbreak invested EUR 12 million to support nine projects.
- The 2026 fast-track response to the Ebola outbreak included three Ebola calls focused on capacity building, emergency research and outbreak intervention tools, with a total mobilisation of EUR 124.9 million.
- Investments by type of intervention amount to a total grant value of EUR 1.4 billion.
- These investments cover cross-intervention or intervention-unspecific projects, diagnostics, other prevention tools, surveillance tools, therapies and vaccines.
- Project participants include education and research partners, as well as industry actors, especially pharmaceutical companies, biotech companies and SMEs.
- The partnership places strong emphasis on vulnerable populations.

Projects portfolio

- ODIN-MPox 2024-26
 - Applying genomic technologies to wastewater surveillance to track the spread of mpox.
- EBO-PEP 2024-27
 - Evaluating whether monoclonal antibodies can protect close contacts of people with Ebola virus infections.
- DENSTAR 2026-30
 - Generating evidence to support the safety, immunogenicity and registration of a novel single-dose tetravalent dengue vaccine.
- MultiplexAI 2025-29
 - Developing an AI-based add-on for conventional microscopes to detect parasite infections.
- ResTick 2025-28

- Providing a model approach for monitoring ticks and the presence of Crimean-Congo haemorrhagic fever (CCHF) virus.
- ComBac-Africa 2025-29
 - Improving access to new antibiotics and incorporating measures to limit drug resistance.
- CT-Luso 2024-27
 - Developing ethical review and regulatory capacity in Portuguese-speaking countries.
- GREAT-LIFE – 2023-28
 - Building a genomics-based infrastructure to track infectious disease threats and AMR genes in the Great Lakes region.
- SINCEP-Africa 2026-31
 - Building on an existing network of community-based research sites to strengthen epidemic and clinical research capacity.

Scientific leadership

- Participation in Horizon projects usually requires entities to be based in the EU or in an associated country, which has made participation almost impossible for many African countries.
- Global Health EDCTP3, therefore, also brings symbolic recognition of African countries and their role in scientific leadership.
- The partnership helps boost Europe's competitiveness and scientific leadership by fostering research excellence, public-private partnerships and international collaboration.
- Relevant case studies include the first malaria vaccines and networks of excellence.
- The partnership also supports Europe's values and standards in science, diplomacy and human rights.
- One example is the development of the first medicine against schistosomiasis for pre-school children.
- EDCTP3 is a funding model built on trust, with a strong focus on equity, impact and the future.